세계의 협심증 치료제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Angina Pectoris Drugs Market is presumed to reach the market size of nearly USD 16.25 Billion by 2032 from USD 11.69 Billion in 2023 with a CAGR of 3.73% under the study period 2024-2032.

Angina pectoris drugs are medications used to relieve and manage the chest pain associated with angina, a disorder caused by reduced blood flow to the heart muscle. Common classes of these drugs include nitrates (e.g., nitroglycerin), beta-blockers (e.g., metoprolol), calcium channel blockers (e.g., amlodipine), and antiplatelet agents (e.g., aspirin). These medications work by dilating blood vessels, lowering heart workload, and preventing blood clots, thereby improving oxygen delivery to the heart. Effective management of angina pectoris with these drugs helps lower the frequency and severity of angina attacks, improve quality of life, and prevent complications such as heart attacks.

MARKET DYNAMICS

The proliferating prevalence of cardiovascular diseases leads to a higher incidence of angina pectoris and, consequently, a greater demand for effective angina pectoris drugs. Advances in pharmaceutical research have resulted in the development of new and improved angina pectoris drugs that offer better efficacy and safety profiles, making them more appealing to patients & healthcare providers. Additionally, the aging global population, which is more prone to cardiovascular conditions, significantly boosts the demand for these medications. The growing awareness about the significance of early diagnosis and management of angina pectoris among patients and healthcare providers further drives market growth. Moreover, supportive government initiatives & healthcare policies aimed at lowering the burden of cardiovascular diseases play an integral role in market growth. Increased healthcare expenditure and expanding healthcare infrastructure, particularly in emerging economies, enhance the accessibility and availability of angina pectoris drugs. Furthermore, the rising adoption of lifestyle changes & preventive measures to manage and lower the risk of cardiovascular diseases also contributes to the demand for these drugs. However, high costs and potential side effects may challenge market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Angina Pectoris Drugs. The growth and trends of Angina Pectoris Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Angina Pectoris Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Therapeutic Class

• Beta Blockers
• Calcium Antagonists
• Anticoagulants
• Anti-Platelets
• Others (Nitrates, Anti-anginal (Ranolazine), ACE Inhibitors)'

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Angina Pectoris Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Angina Pectoris Drugs market include Amgen Inc., Sanofi S.A., Gilead Sciences Inc., AstraZeneca Plc., GlaxoSmithKline Plc., Eli Lilly And Company, Pfizer Inc., Novartis AG, XyloCor Therapeutics Inc., Tasly Pharmaceuticals Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. ANGINA PECTORIS DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Therapeutic Class
  • 3.7.2 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ANGINA PECTORIS DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS

• 5.1. Overview By Therapeutic Class
• 5.2. Historical and Forecast Data Analysis By Therapeutic Class
• 5.3. Beta Blockers Historic and Forecast Sales By Regions
• 5.4. Calcium Antagonists Historic and Forecast Sales By Regions
• 5.5. Anticoagulants Historic and Forecast Sales By Regions
• 5.6. Anti-Platelets Historic and Forecast Sales By Regions
• 5.7. Others (Nitrates, Anti-anginal (Ranolazine), ACE Inhibitors)' Historic and Forecast Sales By Regions

6. GLOBAL ANGINA PECTORIS DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 6.1. Regional Outlook
• 6.2. Introduction
• 6.3. North America Sales Analysis
  • 6.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.3.2 North America By Segment Sales Analysis
  • 6.3.3 North America By Country Sales Analysis
  • 6.3.4 United States Sales Analysis
  • 6.3.5 Canada Sales Analysis
  • 6.3.6 Mexico Sales Analysis
• 6.4. Europe Sales Analysis
  • 6.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.4.2 Europe By Segment Sales Analysis
  • 6.4.3 Europe By Country Sales Analysis
  • 6.4.4 United Kingdom Sales Analysis
  • 6.4.5 France Sales Analysis
  • 6.4.6 Germany Sales Analysis
  • 6.4.7 Italy Sales Analysis
  • 6.4.8 Russia Sales Analysis
  • 6.4.9 Rest Of Europe Sales Analysis
• 6.5. Asia Pacific Sales Analysis
  • 6.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.5.2 Asia Pacific By Segment Sales Analysis
  • 6.5.3 Asia Pacific By Country Sales Analysis
  • 6.5.4 China Sales Analysis
  • 6.5.5 India Sales Analysis
  • 6.5.6 Japan Sales Analysis
  • 6.5.7 South Korea Sales Analysis
  • 6.5.8 Australia Sales Analysis
  • 6.5.9 South East Asia Sales Analysis
  • 6.5.10 Rest Of Asia Pacific Sales Analysis
• 6.6. Latin America Sales Analysis
  • 6.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.6.2 Latin America By Segment Sales Analysis
  • 6.6.3 Latin America By Country Sales Analysis
  • 6.6.4 Brazil Sales Analysis
  • 6.6.5 Argentina Sales Analysis
  • 6.6.6 Peru Sales Analysis
  • 6.6.7 Chile Sales Analysis
  • 6.6.8 Rest of Latin America Sales Analysis
• 6.7. Middle East & Africa Sales Analysis
  • 6.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 6.7.2 Middle East & Africa By Segment Sales Analysis
  • 6.7.3 Middle East & Africa By Country Sales Analysis
  • 6.7.4 Saudi Arabia Sales Analysis
  • 6.7.5 UAE Sales Analysis
  • 6.7.6 Israel Sales Analysis
  • 6.7.7 South Africa Sales Analysis
  • 6.7.8 Rest Of Middle East And Africa Sales Analysis

7. COMPETITIVE LANDSCAPE OF THE ANGINA PECTORIS DRUGS COMPANIES

• 7.1. Angina Pectoris Drugs Market Competition
• 7.2. Partnership/Collaboration/Agreement
• 7.3. Merger And Acquisitions
• 7.4. New Product Launch
• 7.5. Other Developments

8. COMPANY PROFILES OF ANGINA PECTORIS DRUGS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Market Concentration Rate
• 8.3. Amgen Inc.
  • 8.3.1 Company Overview
  • 8.3.2 Company Revenue
  • 8.3.3 Products
  • 8.3.4 Recent Developments
• 8.4. Sanofi S.A.
  • 8.4.1 Company Overview
  • 8.4.2 Company Revenue
  • 8.4.3 Products
  • 8.4.4 Recent Developments
• 8.5. Gilead Sciences Inc.
  • 8.5.1 Company Overview
  • 8.5.2 Company Revenue
  • 8.5.3 Products
  • 8.5.4 Recent Developments
• 8.6. AstraZeneca Plc.
  • 8.6.1 Company Overview
  • 8.6.2 Company Revenue
  • 8.6.3 Products
  • 8.6.4 Recent Developments
• 8.7. GlaxoSmithKline Plc.
  • 8.7.1 Company Overview
  • 8.7.2 Company Revenue
  • 8.7.3 Products
  • 8.7.4 Recent Developments
• 8.8. Eli Lilly And Company
  • 8.8.1 Company Overview
  • 8.8.2 Company Revenue
  • 8.8.3 Products
  • 8.8.4 Recent Developments
• 8.9. Pfizer Inc.
  • 8.9.1 Company Overview
  • 8.9.2 Company Revenue
  • 8.9.3 Products
  • 8.9.4 Recent Developments
• 8.10. Novartis AG
  • 8.10.1 Company Overview
  • 8.10.2 Company Revenue
  • 8.10.3 Products
  • 8.10.4 Recent Developments
• 8.11. XyloCor Therapeutics Inc.
  • 8.11.1 Company Overview
  • 8.11.2 Company Revenue
  • 8.11.3 Products
  • 8.11.4 Recent Developments
• 8.12. Tasly Pharmaceuticals Inc
  • 8.12.1 Company Overview
  • 8.12.2 Company Revenue
  • 8.12.3 Products
  • 8.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies